ACTH as first line treatment for acute gout in 181 hospitalized patients

Joint Bone Spine

Volumn 80, Issue 3, 2013, Pages 291-294

  Daoussis, Dimitrios ^a   Antonopoulos, Ioannis ^a   Yiannopoulos, Georgios ^a   Andonopoulos, Andrew P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

ACTH; Comorbidities; Crystal induced arthritis; Gout; Hospitalized patients; Uric acid

Indexed keywords

COLCHICINE; CORTICOTROPIN; GLUCOSE; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; STEROID; HORMONE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CONSULTATION; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GOUT; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT IDENTIFICATION; POTASSIUM BLOOD LEVEL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; TREATMENT RESPONSE; ACUTE DISEASE; ARTHRITIS, GOUTY; COMORBIDITY; HOSPITALIZATION; TREATMENT OUTCOME;

ACUTE DISEASE; ADRENOCORTICOTROPIC HORMONE; AGED; ARTHRITIS, GOUTY; COMORBIDITY; FEMALE; GOUT; HORMONES; HOSPITALIZATION; HUMANS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84878375365     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.09.009     Document Type: Article

References (25)

1. Jordan K.M., Cameron J.S., Snaith, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007, 46:1372-1374.
2. Zhang W., Doherty M., Bardin T., et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.
3. Hamburger M., Baraf H.S., Adamson T.C., et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med 2011, 123:3-36.
4. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003, 139:137-147.
5. Keenan R.T., O'Brien W.R., Lee K.H., et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011, 124:155-163.
6. Liote F., Lancrenon S., Lanz S., et al. GOSPEL: prospective survey of gout in France. Part I: design and patient characteristics (n=1003). Joint Bone Spine 2012, 10.1016/j.jbspin.2011.12.006.
7. Gutman A.B., Yu T.F. Effects of adrenocorticotropic hormone (ACTH) in gout. Am J Med 1950, 9:24-30.
8. Axelrod D., Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988, 31:803-805.
9. Siegel L.B., Alloway J.A., Nashel D.J. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994, 21:1325-1327.
10. Getting S.J., Christian H.C., Flower R.J., et al. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002, 46:2765-2775.
11. Wallace S.L., Robinson H., Masi A.T., et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977, 20:895-900.
12. Traynor J., Mactier R., Geddes C.C., et al. How to measure renal function in clinical practice. BMJ 2006, 333:733-737.
13. Bavry A.A., Khaliq A., Gong Y., et al. Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. Am J Med 2011, 124:614-620.
14. Schjerning Olsen A.M., Fosbøl E.L., Lindhardsen J., et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011, 123:2226-2235.
15. Terkeltaub R.A., Furst D.E., Digiacinto J.L., et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum 2011, 63:2226-2237.
16. Mullins M., Cannarozzi A.A., Bailey T.C., et al. Unrecognized fatalities related to colchicine in hospitalized patients. Clin Toxicol (Phila) 2011, 49:648-652.
17. Ritter J., Kerr L.D., Valeriano-Marcet J., et al. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994, 21:696-699.
18. Neogi T. Clinical practice. Gout. N Engl J Med 2011, 364:443-452.
19. Getting S.J. Targeting melanocortin receptors as potential novel therapeutics. Pharmacol Ther 2006, 111:1-15.
20. Getting S.J., Perretti M. Arthritic diseases: melanocortin type 3 receptor agonists as potential therapeutics. Curr Opin Investig Drugs 2001, 2:1064-1069.
21. Getting S.J., Allcock G.H., Flower R., et al. Natural and synthetic agonists of the melanocortin receptor type 3 possess anti-inflammatory properties. J Leukoc Biol 2001, 69:98-104.
22. Getting S.J., Lam C.W., Chen A.S., et al. Melanocortin 3 receptors control crystal-induced inflammation. FASEB J 2006, 20:2234-2241.
23. Getting S.J., Gibbs L., Clark A.J., et al. POMC gene-derived peptides activate melanocortin type 3 receptor on murine macrophages, suppress cytokine release, and inhibit neutrophil migration in acute experimental inflammation. J Immunol 1999, 162:7446-7453.
24. So A., De Smedt T., Revaz S., et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28.
25. Schlesinger N., Alten R.E., Bardin T., et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012, 71:1839-1843.